Paritaprevir, formerly known as ABT-450, is an NS3/4A protease inhibitor discovered during the ongoing collaboration between Enanta and AbbVie for HCV protease inhibitors and regimens that include protease inhibitors.
Paritaprevir Marketing Status
On December xx, 2014, the U.S. Food and Drug Administration (FDA) granted marketing approval for AbbVie’s VIEKIRA PAK™ for the treatment of chronic hepatitis C virus (HCV) infection including those with compensated cirrhosis. Paritaprevir is one of three direct-acting antivirals in AbbVie’s VIEKIRA PAK™ which consists of the fixed-dose combination of ombitasvir 25mg (an NS5A inhibitor), paritaprevir 150mg (an NS3/4A protease inhibitor), and ritonavir 100mg (an approved HIV-1 protease inhibitor), dosed once daily, and dasabuvir 250mg (a non-nucleoside NS5B polymerase inhibitor), dosed twice daily. Depending on the specific population, ribavirin may also be indicated for co-administration. AbbVie is responsible for marketing VIEKIRA PAK™ in the U.S.
Paritaprevir, Enanta’s lead HCV candidate formerly known as ABT-450 was discovered during the ongoing collaboration between Enanta and AbbVie for HCV protease inhibitors and regimens that include protease inhibitors. Paritaprevir is being developed by AbbVie for use in combination with AbbVie’s other investigational medicines for the treatment of HCV. AbbVie is developing paritaprevir in a two-direct-acting-antiviral (2-DAA) treatment regimen and a three-direct-acting-antiviral (3-DAA) treatment regimen for HCV. Visit Enanta’s research page for more information on Enanta’s development pipeline.
AbbVie is responsible for all worldwide development and commercialization of VIEKIRA PAK. In addition to the U.S. marketing approval in December 2014, applications for approval of multi-drug regimens containing paritaprevir were accepted for European Medicines Agency regulatory review in the European Union in the second quarter of 2014. For additional information on VIEKIRA PAK and prescribing information please visit www.abbvie.com.